Marburg virus, a member of the ... It binds to an epitope in the wing region of Marburg virus glycoprotein, targeting the GP2 wing. The protection was mediated by the Fc fragment functions of ...

Flagged as a potential pandemic-causing virus, this is the first Marburg vaccine to move into Phase 2 human trials. ... uses an adenovirus vector to deliver a Marburg glycoprotein.

An experimental vaccine for Marburg virus—a deadly cousin of the infectious agent that causes Ebola—can ... an adenovirus-vectored shot that expresses the Marburg virus (MARV) glycoprotein.

These monoclonal antibodies bind to the envelope protein of Marburg virus called glycoprotein but do not kill the virus. Instead, they recruit immune cells that contribute by killing infected cells.

Scientists have discovered the workings of the first promising treatment for Marburg virus, a pathogen with the same pandemic potential as Ebola virus. With a mortality rate of up to 88 percent ...

A deadly, Ebola-like virus called Marburg is currently causing an outbreak in Rwanda. The country declared an outbreak of Marburg virus disease on Sept. 27 and has reported 58 confirmed cases and ...

In a recent Pathogens review article, researchers discuss the development and structural characterization of therapeutic monoclonal antibodies targeting the surface glycoprotein of filoviruses ...

The Marburg virus vaccine was based on the glycoprotein from the Angola strain, and the Ebola vaccine was based on glycoproteins from the Zaire and Sudan species. (The current Ebola outbreak in ...

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

An experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. genprowebdirectory Facebook Linkedin RSS Twitter Youtube ...

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine ...

They showed that glycoprotein-mediated infection is substantially reduced in cells lacking these proteases; that cathepsin B and cathepsin L can individually cleave Ebola virus GP1 to yield an ...